Mesa Laboratories, Inc (NASDAQ:MLAB) Anticipates Near-Term Margin Recovery And Share Revaluation

Robust gross margins and a fresh dividend declaration underscore operational resilience, while mixed momentum indicators signal short-term pressure before potential revaluation.

Recent News

On April 2, 2026 the Board declared a quarterly cash dividend of $0.16 per share, payable June 15, 2026 to shareholders of record on May 29, 2026. The company filed its 2026 annual report and related SEC disclosures during the spring reporting window, which also documented corporate governance and dividend timing.

Technical Analysis

ADX registers 15.78, indicating no established directional trend; this lowers conviction in breakout scenarios and aligns with the short-term technical congestion suggested elsewhere.

Directional indicators show bearish orientation: DI+ at 18.90 produced a peak-and-reversal (bearish), while DI- at 25.52 produced a dip-and-reversal (bearish). Those directional signals favor near-term downside pressure relative to recent price levels.

MACD sits at 0.46 with the MACD line declining below the signal line at 1.50, a bearish momentum configuration that reduces the likelihood of immediate upside follow-through until momentum stabilizes.

MRO equals -20.92 (negative and decreasing), which indicates the market price lies below the model target and therefore contains technical potential for mean reversion to the upside if momentum pivots; this creates a counterweight to currently bearish momentum signals.

RSI at 51.64 with a peak-and-reversal points to a recent loss of upward momentum rather than oversold conditions, reinforcing the near-term pressure implied by MACD and directional indicators.

Price trades at $94.95 below the 20-day average ($104.83) and recent short-term EMAs (12-day EMA peaked and reversed), yet remains above the 200-day average ($84.57). That structural split suggests shorter-term resistance with underlying longer-term support, leaving the stock susceptible to range-bound action until momentum confirms a direction.

 


Fundamental Analysis

Mesa reported total revenue of $63,724,000 and gross profit of $42,205,000; gross margin stands at 66.23%, above the industry peer mean of 63.52%, supporting stronger product-level profitability. Operating margin equals 4.31%, materially below the industry peer mean of 20.47%, reflecting higher operating leverage and near-term cost pressure. EBIT amounts to $1,003,000 (EBIT margin 1.57%), versus an industry peer mean EBIT margin of 20.35%.

Profitability trends show contraction: EBIT margin declined roughly 86.6% quarter-over-quarter and about 67.2% year-over-year, while operating margin declined roughly 64.8% QoQ and 10.1% YoY. Net income registered a loss of $4,136,000 for the period, and return on equity equals -2.22%.

Earnings per share came in at $1.83 versus an estimate of $1.39, a beat of $0.44 or +31.66% (EPS surprise). The EPS beat reflects a combination of margin dynamics and non-operating items disclosed in the fiscal release.

Cash and liquidity: cash and short-term investments total $26,928,000 with operating cash flow of $13,962,000 and free cash flow of $13,545,000, producing a free cash flow yield near 2.55%. The current ratio equals 1.72 and the quick ratio 1.29, signaling adequate near-term liquidity despite working capital seasonality (cash conversion cycle ~144 days).

Leverage and capital structure: total debt equals $155,169,000 with debt-to-assets at 36.28%, slightly above the industry peer mean of 26.90%; debt-to-EBITDA reads ~22.98, indicating elevated leverage relative to operating earnings. Intangible assets remain large at $270,210,000 and net tangible assets negative, underscoring balance-sheet composition considerations.

Growth metrics present a mixed picture: reported revenue growth YoY stands at +91.89% while sequential revenue change shows a substantial decline QoQ of -129.80% (both reported data points). Earnings growth sits at +3.98%, which compares favorably to the industry peer mean of -14.30%.

Valuation context: WMDST values the stock as under-valued. Key valuation multiples include a PE of 52.48, EV/revenue roughly 10.34, price-to-book 2.85, and price-to-sales 8.33. Free cash generation and a modest dividend ($0.16 quarterly) lend income support, while elevated leverage and recent margin compression cap the valuation uplift until operating margins stabilize.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-05-27
NEXT REPORT DATE: 2026-08-26
CASH FLOW  Begin Period Cash Flow 29.0 M
 Operating Cash Flow 14.0 M
 Capital Expenditures -417.00 K
 Change In Working Capital 3.9 M
 Dividends Paid -884.00 K
 Cash Flow Delta -2.05 M
 End Period Cash Flow 26.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 63.7 M
 Forward Revenue -65.28 M
COSTS
 Cost Of Revenue 21.5 M
 Depreciation 1.3 M
 Depreciation and Amortization 5.8 M
 Research and Development 5.2 M
 Total Operating Expenses 61.0 M
PROFITABILITY
 Gross Profit 42.2 M
 EBITDA 6.8 M
 EBIT 1.0 M
 Operating Income 2.7 M
 Interest Income
 Interest Expense 2.6 M
 Net Interest Income -2.60 M
 Income Before Tax -1.59 M
 Tax Provision 2.5 M
 Tax Rate 40.0 %
 Net Income -4.14 M
 Net Income From Continuing Operations -4.14 M
EARNINGS
 EPS Estimate 1.39
 EPS Actual 1.83
 EPS Difference 0.44
 EPS Surprise 31.655 %
 Forward EPS 3.07
 
BALANCE SHEET ASSETS
 Total Assets 427.7 M
 Intangible Assets 270.2 M
 Net Tangible Assets -83.97 M
 Total Current Assets 106.3 M
 Cash and Short-Term Investments 26.9 M
 Cash 26.9 M
 Net Receivables 44.1 M
 Inventory 26.4 M
 Long-Term Investments 19.2 M
LIABILITIES
 Accounts Payable 4.9 M
 Short-Term Debt 5.6 M
 Total Current Liabilities 61.9 M
 Net Debt 124.6 M
 Total Debt 155.2 M
 Total Liabilities 241.5 M
EQUITY
 Total Equity 186.2 M
 Retained Earnings -185.75 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 33.71
 Shares Outstanding 5.525 M
 Revenue Per-Share 11.53
VALUATION
 Market Capitalization 530.6 M
 Enterprise Value 658.9 M
 Enterprise Multiple 97.565
Enterprise Multiple QoQ 119.037 %
Enterprise Multiple YoY 25.754 %
Enterprise Multiple IPRWA high: 167.868
MLAB: 97.565
mean: 82.374
median: 80.811
low: -193.913
 EV/R 10.339
CAPITAL STRUCTURE
 Asset To Equity 2.297
 Asset To Liability 1.771
 Debt To Capital 0.454
 Debt To Assets 0.363
Debt To Assets QoQ -12.838 %
Debt To Assets YoY -13.375 %
Debt To Assets IPRWA high: 0.725
MLAB: 0.363
mean: 0.269
median: 0.249
low: 0.002
 Debt To Equity 0.833
Debt To Equity QoQ -14.056 %
Debt To Equity YoY -26.622 %
Debt To Equity IPRWA high: 4.524
MLAB: 0.833
mean: 0.544
median: 0.426
low: -0.465
PRICE-BASED VALUATION
 Price To Book (P/B) 2.849
Price To Book QoQ 20.198 %
Price To Book YoY -30.87 %
Price To Book IPRWA high: 20.943
mean: 5.624
median: 4.172
MLAB: 2.849
low: -12.173
 Price To Earnings (P/E) 52.481
Price To Earnings QoQ 15.322 %
Price To Earnings YoY -156.852 %
Price To Earnings IPRWA high: 194.313
mean: 120.349
median: 98.047
MLAB: 52.481
low: -198.766
 PE/G Ratio 13.196
 Price To Sales (P/S) 8.327
Price To Sales QoQ 22.549 %
Price To Sales YoY -21.454 %
Price To Sales IPRWA high: 62.134
mean: 29.52
median: 21.968
MLAB: 8.327
low: 0.285
FORWARD MULTIPLES
Forward P/E 27.46
Forward PE/G 6.905
Forward P/S -8.128
EFFICIENCY OPERATIONAL
 Operating Leverage 40.347
ASSET & SALES
 Asset Turnover Ratio 0.148
Asset Turnover Ratio QoQ -1.86 %
Asset Turnover Ratio YoY 3.495 %
Asset Turnover Ratio IPRWA high: 0.411
MLAB: 0.148
median: 0.128
mean: 0.122
low: 0.002
 Receivables Turnover 1.511
Receivables Turnover Ratio QoQ -6.801 %
Receivables Turnover Ratio YoY -1.96 %
Receivables Turnover Ratio IPRWA high: 3.141
mean: 1.938
median: 1.582
MLAB: 1.511
low: 0.361
 Inventory Turnover 0.813
Inventory Turnover Ratio QoQ -5.387 %
Inventory Turnover Ratio YoY -8.34 %
Inventory Turnover Ratio IPRWA high: 2.164
MLAB: 0.813
mean: 0.607
median: 0.509
low: 0.137
 Days Sales Outstanding (DSO) 60.38
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 143.982
Cash Conversion Cycle Days QoQ 1.429 %
Cash Conversion Cycle Days YoY -1.022 %
Cash Conversion Cycle Days IPRWA high: 587.726
median: 180.7
mean: 160.417
MLAB: 143.982
low: -133.614
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 1.436
 CapEx To Revenue -0.007
 CapEx To Depreciation -0.33
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 332.1 M
 Net Invested Capital 337.7 M
 Invested Capital 337.7 M
 Net Tangible Assets -83.97 M
 Net Working Capital 44.4 M
LIQUIDITY
 Cash Ratio 0.435
 Current Ratio 1.717
Current Ratio QoQ -11.593 %
Current Ratio YoY 174.134 %
Current Ratio IPRWA high: 14.36
mean: 2.73
median: 2.112
MLAB: 1.717
low: 0.038
 Quick Ratio 1.291
Quick Ratio QoQ -11.208 %
Quick Ratio YoY 173.713 %
Quick Ratio IPRWA high: 12.588
mean: 2.016
median: 1.518
MLAB: 1.291
low: 0.37
COVERAGE & LEVERAGE
 Debt To EBITDA 22.978
 Cost Of Debt 0.927 %
 Interest Coverage Ratio 0.386
Interest Coverage Ratio QoQ -84.631 %
Interest Coverage Ratio YoY -67.341 %
Interest Coverage Ratio IPRWA high: 87.935
mean: 17.93
median: 13.911
MLAB: 0.386
low: -102.892
 Operating Cash Flow Ratio -0.039
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 19.909
DIVIDENDS
 Dividend Coverage Ratio -4.679
 Dividend Payout Ratio -0.214
 Dividend Rate 0.16
 Dividend Yield 0.002
PERFORMANCE GROWTH
 Asset Growth Rate -1.633 %
 Revenue Growth -2.153 %
Revenue Growth QoQ -129.795 %
Revenue Growth YoY 91.889 %
Revenue Growth IPRWA high: 16.503 %
MLAB: -2.153 %
median: -5.375 %
mean: -7.834 %
low: -65.483 %
 Earnings Growth 3.977 %
Earnings Growth QoQ -98.634 %
Earnings Growth YoY -99.015 %
Earnings Growth IPRWA high: 200.0 %
MLAB: 3.977 %
median: -7.623 %
mean: -14.297 %
low: -145.833 %
MARGINS
 Gross Margin 66.231 %
Gross Margin QoQ 3.202 %
Gross Margin YoY 7.135 %
Gross Margin IPRWA high: 95.029 %
MLAB: 66.231 %
mean: 63.517 %
median: 63.289 %
low: 7.731 %
 EBIT Margin 1.574 %
EBIT Margin QoQ -86.569 %
EBIT Margin YoY -67.181 %
EBIT Margin IPRWA high: 63.148 %
median: 21.811 %
mean: 20.348 %
MLAB: 1.574 %
low: -233.035 %
 Return On Sales (ROS) 4.312 %
Return On Sales QoQ -64.786 %
Return On Sales YoY -10.092 %
Return On Sales IPRWA high: 63.148 %
median: 20.603 %
mean: 20.468 %
MLAB: 4.312 %
low: -219.267 %
CASH FLOW
 Free Cash Flow (FCF) 13.5 M
 Free Cash Flow Yield 2.553 %
Free Cash Flow Yield QoQ -37.319 %
Free Cash Flow Yield YoY 44.237 %
Free Cash Flow Yield IPRWA high: 7.748 %
MLAB: 2.553 %
mean: 0.515 %
median: 0.47 %
low: -15.26 %
 Free Cash Growth -24.842 %
Free Cash Growth QoQ -116.262 %
Free Cash Growth YoY -26.631 %
Free Cash Growth IPRWA high: 324.237 %
MLAB: -24.842 %
mean: -32.299 %
median: -37.858 %
low: -397.308 %
 Free Cash To Net Income -3.275
 Cash Flow Margin -3.752 %
 Cash Flow To Earnings 0.578
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) -0.959 %
Return On Assets QoQ -214.303 %
Return On Assets YoY -41.31 %
Return On Assets IPRWA high: 5.251 %
mean: 2.049 %
median: 1.583 %
MLAB: -0.959 %
low: -28.223 %
 Return On Capital Employed (ROCE) 0.274 %
 Return On Equity (ROE) -0.022
Return On Equity QoQ -214.249 %
Return On Equity YoY -50.101 %
Return On Equity IPRWA high: 0.413
median: 0.032
mean: 0.03
MLAB: -0.022
low: -0.899
 DuPont ROE -2.218 %
 Return On Invested Capital (ROIC) 0.178 %
Return On Invested Capital QoQ -89.578 %
Return On Invested Capital YoY -74.462 %
Return On Invested Capital IPRWA high: 8.753 %
mean: 2.447 %
median: 2.32 %
MLAB: 0.178 %
low: -14.938 %

Six-Week Outlook

Expect short-term sideways-to-lower action while MACD momentum and directional indicators remain bearish and price trades below short-term averages. The negative MRO leaves scope for an intrawindow bounce if buyers target a reversion toward the model price; any sustained move above the 20-day average and a MACD re-acceleration would signal reduced short-term downside risk. Traders should watch DI+/DI- behavior and the RSI for confirmation of momentum shifts; absent that confirmation, range-bound selling pressure should dominate.

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. (NASDAQ:MLAB) develops and manufactures a diverse range of life sciences tools and quality control products. Serving markets across North America, Europe, the Asia Pacific, and globally, Mesa Laboratories addresses critical needs in various industries. The Sterilization and Disinfection Control segment provides biological, chemical, and cleaning indicators, essential for evaluating sterilization and decontamination processes in the pharmaceutical, medical device, and healthcare sectors. This segment also extends testing and laboratory services to dental and pharmaceutical industries. In the Clinical Genomics segment, Mesa Laboratories offers the MassARRAY system, a genetic analysis tool, along with consumables like chips, panels, and chemical reagents. These tools support clinical labs in DNA sample analysis for genetic disease testing, pharmacogenetics, oncology, and more. The Biopharmaceutical Development segment delivers automated systems for protein analysis and peptide synthesis, including Gyrolab and PurePep product lines. The Calibration Solutions segment provides quality control products for measuring critical parameters in environmental and process monitoring, as well as medical device and pharmaceutical manufacturing. Products include continuous monitoring systems, dialysate meters, data loggers, and gas flow calibration equipment, marketed under brands such as DialyGuard, ViewPoint, and DataTrace. Established in 1982, Mesa Laboratories is headquartered in Lakewood, Colorado.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.